OGN - Organon & Co. Latest News | Finranks

27.03.2026

Organon (OGN) Suffers a Larger Drop Than the General Market: Key Insights

In the latest trading session, Organon (OGN) closed at $5.84, marking a -3.47% move from the previous day.

27.03.2026

Organon Debuts New Analysis of VTAMA® (tapinarof) cream, 1%, Phase 3 Pooled Data Demonstrating Early and Consistent Skin Clearance and Itch Improvement in Atopic Dermatitis Patients Down to 2 Years of Age

JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon's VTAMA (tapinarof) cream, 1% new Phase 3 pooled data analysis shows early and consistent skin clearance and itch improvements for AD patients.

20.03.2026

Does This $25 Million Bet on a Stock Down 61% Signal Turnaround Potential at $6?

Sio initiated a new OGN position in the fourth quarter, buying up 3,421,765 shares. The quarter-end position value increased by $24.53 million as a result.

20.03.2026

US FDA flags seizure risk with certain Parkinson's drugs, seeks label warnings

The U.S. Food and Drug Administration said on Friday it has notified manufacturers of certain Parkinson's disease treatments to update their prescribing information with a new warning about ‌a potential risk of seizures.

18.03.2026

Organon (OGN) Falls More Steeply Than Broader Market: What Investors Need to Know

Organon (OGN) closed at $6.23 in the latest trading session, marking a -2.5% move from the prior day.

17.03.2026

Investors Heavily Search Organon & Co. (OGN): Here is What You Need to Know

Zacks.com users have recently been watching Organon (OGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

03.03.2026

KDventures announces that Organon has discontinued the development of the previous portfolio company Forendos' drug candidate for PCOS

STOCKHOLM, Sweden, March 3, 2026. KDventures AB (Nasdaq Stockholm: KDV) today announces that Organon has discontinued the development of a preclinical drug candidate for polycystic ovarian syndrome (PCOS) that was part of the acquisition of the portfolio company Forendo. Thus, the development of both drug candidates included in the acquisition has been discontinued. KDventures will therefore write off its entire remaining book value of the agreement on potential additional purchase considerations entered into between the parties in connection with the acquisition.

Videos

No Data

There is no data to display

Upgrades / Downgrades

Ticker	Brokerage Firm	Ratings Change	Price Target	Date
OGN	Evercore ISI	In-line	undefined >> undefined	May 2nd 2025
OGN	JP Morgan	Underweight	$18 >> $20	September 6th 2024
OGN	Goldman	Neutral	$33 >> $16	November 3rd 2023
OGN	Barclays	Overweight	undefined >> $28	September 21st 2023
OGN	Raymond James	Outperform	undefined >> $33	March 16th 2023
OGN	BofA Securities	Underperform	$27 >> $25	October 14th 2022
OGN	Piper Sandler	Overweight	$37 >> $34	September 6th 2022
OGN	Goldman	Buy	undefined >> $40	April 27th 2022

Organon & Co. (OGN)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us